Dateline City:
KENILWORTH, N.J.
KEYNOTE-024 Studied Patients Whose Tumors Expressed High Levels of PD-L1
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the KEYNOTE-024 trial investigating the use of
KEYTRUDA (pembrolizumab), in patients with previously
untreated advanced non-small cell lung cancer (NSCLC) whose tumors
expressed high levels of PD-L1 (tumor proportion score of 50 percent or
more), met its primary endpoint.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more